AlphAIalphai — Financial news for AI agents
scanx.tradeSEP 42 min read$MDT

Medtronic Q1 EPS beats at $1.45; analysts raise price targets

Medtronic (MDT) reported Q1 fiscal 2027 adjusted EPS of $1.45, beating estimates by 4.32%. Sales reached $9.756B, up 13.73% YoY. Analysts raised price targets. The company increased its fiscal 2027 guidance and announced strategic investments in robotics and structural heart technologies. Shares rose 1.86% in early trading.

Original reporting
scanx.trade
Published Sep 4, 2026, 12:59 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 4, 2026, 6:40 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Medtronic Q1 EPS beats at $1.45; analysts raise price targets — source image
Source · scanx.trade
Decision brief

The 30-second read

$MDTBullishHigh
01

Why it matters

The earnings beat and raised outlook are likely to drive short-term price appreciation.

02

Market read

High relevance for traders focused on medtech and healthcare equities.

03

What to watch

Potential supply chain or regulatory risks in new robotics investments.

Relevance 9/10Novelty 9/10Timing: early trading

Background

Medtronic's Q1 earnings beat and guidance raise are the first report of these figures.

Company-level read

Ticker impact

$MDTBullishHigh confidence
Context

Medtronic reported Q1 FY2027 EPS of $1.45 beating estimates and raised FY2027 earnings guidance.

Expected impact

Potential short-term rally as analysts lift price targets.

Evidence & confidence

Beat on earnings and revenue, higher guidance, and analyst target raises indicate bullish sentiment.

Market effects

Sector

Medical technology sector may see broader optimism from Medtronic's beat.

Regional

U.S. healthcare stocks could benefit.

Global

Limited to Medtronic and related medtech peers.

Counterpoint

What could challenge this read

If guidance misses future quarters, the rally could be short-lived.

Key entities

  • Company
    Medtronic

    Medical technology giant reporting earnings.

Read at source← All news

Related articles

SEP 4
$MDTHighAI 9/10

Medtronic invests $700 million in Cornerstone Robotics

Medtronic (MDT) invested $700M in Cornerstone Robotics, a Hong Kong-based surgical robotics firm. The deal includes distribution rights for Cornerstone's Sentire system in select markets outside the US, complementing Medtronic's Hugo RAS system. Medtronic aims to expand access to robotic-assisted surgery and offer more choices to surgeons and health systems.

evertiq.com2 min
SEP 3
$MDTMed

4 Reasons to Buy Medtronic Stock Like There's No Tomorrow

Medtronic (MDT) reported 8.4% revenue growth in fiscal 2026, driven by cardiovascular business. It expects 7.25%-7.75% organic growth in fiscal 2027. Free cash flow rose 4.6% to $5.43B. The company offers a 3.1% yield and has raised dividends for 49 years. Analysts project 14% EPS growth from 2026-2029, with the stock trading at 18x forward earnings.

yahoo.com3 min
SEP 3
$MDTMedAI 8/10

Pulnovo Medical Reports Positive PADN-HF-PH Trial Results In PH-LHD

Pulnovo Medical, a Medtronic subsidiary, reported positive results from its PADN-HF-PH trial in PH-LHD patients, showing a 51% reduction in clinical worsening risk and improved functional capacity. The trial was presented at the ESC Congress 2026 and published in NEJM. PADN has received regulatory approvals in 12 countries and is being expanded to treat WHO Group 2 pulmonary hypertension. Medtronic's stock is currently trading at EUR 79.22, down 2.77%.

rttnews.com2 min
SEP 3
$MDTMedAI 8/10

Medtronic plc Q1 2027 Earnings Call Summary

Medtronic reported Q1 2027 organic revenue growth of 13.7%, driven by strong demand in CRM, CST, and Surgical. Cardiac Ablation Solutions grew 88%, and the company raised FY27 guidance to 7.25%-7.75%. Medtronic plans to separate its Diabetes business and invest in high-growth areas like robotics and neurovascular navigation. Foreign exchange is expected to be a $50M-$150M headwind.

yahoo.com3 min
SEP 3
$MDTHighAI 8/10

Medtronic’s Stars Are Aligning for a Price Recovery

Medtronic (MDT) reported Q1 FY2027 with adjusted operating earnings up 14.9%, adjusted EPS up 15.1%, and free cash flow more than doubling. The company raised revenue and EPS guidance, exceeding consensus. Analysts responded positively, with a consensus Moderate Buy rating and price targets suggesting 10-30% upside. MDT's stock rose 5% premarket. Risks include cybersecurity concerns from a recent breach.

yahoo.com3 min
SEP 2
$MDTMed

Medtronic (MDT) announced CMS granted a New Technology Add-on Payment (NTAP) for its INFUSE™ Bone Graft for TLIF, effective October 1, 2026

Medtronic (MDT) announced CMS granted a New Technology Add-on Payment (NTAP) for its INFUSE™ Bone Graft for TLIF, effective October 1, 2026. NTAP provides additional reimbursement for hospitals using new technologies, supporting adoption and patient access. INFUSE™ is the first and only growth factor technology approved for spine fusion procedures, receiving FDA approval earlier this year. This milestone highlights Medtronic's commitment to advancing healthcare innovation and expanding access to

orthospinenews.com2 min